controlled release drug delivery

Novo Nordisk
Biotech

Novo inks $1.3B deal to unlock long-acting obesity injectables

The deal combines Nanexa’s long-acting injectable drug delivery platform with Novo's obesity and Type 2 diabetes drugs.
Nick Paul Taylor Sep 25, 2026 4:53am